COVID-19 Pandemic Hampering Launch of New Oncology Trials
A team of researchers conducted a study to assess the impact of the COVID-19 pandemic on the initiation of clinical trials in oncology.
A team of researchers conducted a study to assess the impact of the COVID-19 pandemic on the initiation of clinical trials in oncology.
Study findings demonstrate the rates of immune-related adverse events and flares of the underlying disorders in this patient population.
The EUA was based on data from the randomized, double-blind, placebo-controlled ENSEMBLE trial.
The American Society of Hematology released guidelines for preventing and managing venous thromboembolism in patients with cancer.
Researchers identified the risk factors for chemotherapy-induced peripheral neuropathy in cancer patients treated with paclitaxel or oxaliplatin.
Researchers conducted a randomized superiority trial to determine if a telephone-directed self-care intervention more effectively reduced depressive symptoms in cancer survivors compared with usual care alone.
This fact sheet reviews the current guidelines for coronavirus disease 2019 (COVID-19) vaccination in patients with cancer.
The American Society of Clinical Oncology (ASCO) highlights the past year’s oncologic advances and identifies important areas for future research in its 2021.
Researchers at Memorial Sloan Kettering Cancer Center investigated the incidence of neurologic sequelae of COVID-19 in patients with cancer.
The NHIS identified underlying medical conditions common among cancer survivors, prompting the ACS to recommend prioritizing them to receive the COVID-19 vaccine.